Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Emyria.
RELATED STOCKHEAD STORIES
Health & Biotech
Weed Week: Sydney Uni says it’s okay to CBD ‘n drive, and cannabis-infused drinks on the rise
Health & Biotech
ASX Health Stocks: Anteris implants its novel aortic valve DurAVR into 8 more patients
Health & Biotech
ASX Health Stocks: Vectus jumps 13pc on promising Phase 1 study results
Mining
Lessons from the Masters: Here’s how Twiggy Forrest spreads his investments
News
Closing Bell: Markets go easy peasy lemon squeezy on Anthony Norman Albanese
Health & Biotech
ASX Health Stocks: Ecstasy for Emyria in MDMA trial, Beamtree wins US$7m deal
Health & Biotech
Weed Week: Wastewater doesn’t lie, Aussie cannabis consumption increased in 2021
Health & Biotech
4D Medical CEO hails launch of world’s first dedicated lung scanner, stock price jumps 30pc
News
Weed Week: New Yorkers with cannabis convictions first in line for retail licences, CBX Stock Exchange launches
Health & Biotech
ASX Health Stocks: Cannabis biotech Emyria all set for Phase 1 clinical trial of lead CBD drug
Health & Biotech
ASX Health Stocks: Cochlear’s profit down 28pc in first half, as Estia’s aged care struggles with Omicron outbreak
News
Weed Week: France temporarily overturns CBD ban and Canada gets a classy culinary cannabis facility
Health & Biotech
Weed Week: Cannabis compounds could prevent Covid and Quebec’s no-jab, no-weed rule quadruples vaccinations
News
Winners List: Here are the top 100 ASX small cap stocks for 2021
News
Twiggy’s big 2021: From hydrogen to cannabis, nickel, retreat spas and… cheese?
Health & Biotech
What’s the best pot stock of 2021? And who’s targeting market domination in 2022?
Health & Biotech
